Dr. Marco Schmidt

Chief Scientific Officer, biotx.ai

Abstract

The challenge in drug development is that clinical efficacy cannot be predicted. Success rates, especially in Phase II, when efficacy is tested for the first time, are below 30 percent. Causal AI enables the prediction of clinical efficacy, thus making clinical development more cost-effective and changing the pharma business model. The pursuit of a single blockbuster molecule with annual sales of one billion dollars is being replaced by several molecules with lower revenue potential but equal profitability.

Speaker bio

Marco studied biochemistry in Berlin and Tübingen and began exploring human genetics and machine learning at the University of Cambridge, UK, which led to the founding of biotx.ai GmbH. The company has developed a causal AI to simulate clinical trials, and this technology is now being made available to biotech and pharmaceutical companies. He is also known for his textbook 'Chemical Biology & Drug Discovery'.

Everyone is welcome, space is limited. Registration is required. Subscribe to our newsletter for priority invitation to upcoming events or join the public meetup group.